

# Session 3: Assessing the Immunologic Signature of Clinical Response

- Importance of multi-parameter analysis. What is the evidence?  
Will need to power studies for such endpoints.
  - Tumor signature
  - Peripheral blood signature
  - SNP signature
- What are the specimen types we all need to be collecting to facilitate novel assay development?
  - DNA, RNA, sera, PBMC, tumor?
- How do we integrate these analysis into current clinical trials?
  - All patients, subpopulations?